|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:atccode
|
L04 AC07
|
|
gptkbp:bioavailability
|
gptkb:unknown
|
|
gptkbp:chemical_formula
|
C_20 H_21 N_3 O_6 S
|
|
gptkbp:class
|
gptkb:monoclonal_antibody
|
|
gptkbp:clinical_trial
|
NCT04327388
NCT04356937
NCT04372186
NCT04409262
|
|
gptkbp:contraindication
|
active infections
severe liver impairment
history of gastrointestinal perforation
hypersensitivity to tocilizumab
|
|
gptkbp:dosage_form
|
solution for infusion
solution for injection
|
|
gptkbp:effective_date
|
2010-01-08
|
|
gptkbp:excretion
|
biliary
|
|
gptkbp:formulation
|
lyophilized powder
auto-injector
pre-filled syringe
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Actemra
|
|
gptkbp:indication
|
gptkb:systemic_juvenile_idiopathic_arthritis
moderate to severe rheumatoid arthritis
severe COVID-19 pneumonia
severe cytokine release syndrome
|
|
gptkbp:ingredients
|
gptkb:tocilizumab
|
|
gptkbp:invention
|
2026-03-01
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
approximately 13 days
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:route_of_administration
|
intravenous
subcutaneous
|
|
gptkbp:safety_measures
|
blood tests for liver function
complete blood count monitoring
lipid levels monitoring
monitoring for infections
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
allergic reactions
rash
increased risk of infections
injection site reactions
gastrointestinal perforations
elevated liver enzymes
|
|
gptkbp:targets
|
gptkb:IL-6_receptor
|
|
gptkbp:used_for
|
gptkb:giant_cell_arteritis
gptkb:COVID-19
gptkb:juvenile_idiopathic_arthritis
gptkb:rheumatoid_arthritis
|
|
gptkbp:bfsParent
|
gptkb:Roche_Pharma
|
|
gptkbp:bfsLayer
|
5
|